FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Goddard Glenn (Last) (First) (Middle) C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 (Street)						2. Issuer Name and Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA] 3. Date of Earliest Transaction (Month/Day/Year) 01/01/2024 4. If Amendment, Date of Original Filed (Month/Day/Year)										eck all applic Directo Officer below) EVP dividual or J) Form fi	tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner Officer (give title Other (specify below) below) EVP, Chief Financial Officer idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person			
	MBRIDGE MA 02139															Form filed by More than One Reporting Person				
(City)	R	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																		
		Tab	le I - Nor	ı-Deriv	ativ	e Se	curit	ies A	cqı	uired, l	Dis	osed o	f, or	r Bene	eficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Day/Year) Exe		A. Deemed execution Date, fany Month/Day/Yea		Code (Instr.					Securitie Beneficia Owned F	5. Amount of Securities Beneficially Owned Following Reported		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										Code	v	Amount		(A) or (D)	Price	Transact (Instr. 3 a	tion(s)			,iiisu. 4)
Common Stock 01/03					1/2024					M		3,062	2 A		(1)	45,950			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	Code (Ins				6. Date Exercisab Expiration Date (Month/Day/Year)			Amo Secu Unde Deriv		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exc	ite ercisable		expiration Date	Title	1	Amount or Number of Shares					
Restricted Stock Unit	(1)	01/01/2024			M			3,062	01/	/01/2024 ⁽³	2) 0	3/02/2031		nmon ock	3,062	\$0	3,064		D	

Explanation of Responses:

- 1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
- 2. On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

James Basta, attorney-in-fact

01/03/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.